U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23N5O
Molecular Weight 397.4732
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVOCERANIB

SMILES

C1CCC(C1)(C#N)c2ccc(cc2)NC(=O)c3cccnc3NCc4ccncc4

InChI

InChIKey=WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)

HIDE SMILES / InChI

Molecular Formula C24H23N5O
Molecular Weight 397.4732
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Apatinib is an orally bioavailable, small molecule tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 and used for the treatment of metastatic gastric cancer or gastroesophageal junction cancer that has progressed or relapsed after chemotherapy. To date, second-line ramucirumab and third-line Apatinib are the only anti-angiogenic approaches that have significantly improved the survival of patients with metastatic gastric cancer. Apatinib exhibited potent, highly-selective inhibition of VEGFR-2, c-kit, c-src, and RET tyrosine kinases. The efficacy of Apatinib monotherapy in patients with metastatic gastric cancer or gastroesophageal junction cancer for whom at least two prior chemotherapy regimens had failed was demonstrated in randomized open-label or double-blind phase II trials and a pivotal placebo-controlled phase III trial, all of which were conducted in China. Further clinical experience and long-term pharmacovigilance are required to definitively establish the efficacy and safety profile of Apatinib, including its use in combination with other chemotherapeutic agents.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35968
Gene ID: 3791.0
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
1.0 nM [IC50]
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:31:09 UTC 2021
Edited
by admin
on Fri Jun 25 21:31:09 UTC 2021
Record UNII
5S371K6132
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIVOCERANIB
INN  
Official Name English
RIVOCERANIB [INN]
Common Name English
RIVOCERANIB [USAN]
Common Name English
3-PYRIDINECARBOXAMIDE, N-(4-(1-CYANOCYCLOPENTYL)PHENYL)-2-((4-PYRIDINYLMETHYL)AMINO)-
Systematic Name English
YN968D1 FREE BASE
Code English
APATINIB
Common Name English
N-(4-(1-CYANOCYCLOPENTYL)PHENYL)-2-((PYRIDIN-4-YLMETHYL)AMINO)PYRIDINE-3-CARBOXAMIDE
Systematic Name English
APATINIB FREE BASE
Common Name English
RIVOCERANIB [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
FDA ORPHAN DRUG 798720
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
NCI_THESAURUS C1742
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
NCI_THESAURUS C1967
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
Code System Code Type Description
DRUG CENTRAL
5211
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
DRUG BANK
DB14765
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
INN
10596
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
CAS
811803-05-1
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
EVMPD
SUB183841
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
PUBCHEM
11315474
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
FDA UNII
5S371K6132
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
NCI_THESAURUS
C152237
Created by admin on Fri Jun 25 21:31:09 UTC 2021 , Edited by admin on Fri Jun 25 21:31:09 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
URINE
EXCRETED UNCHANGED
FECAL
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
SELECTIVE
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

AT DAY 28

ONCE DAILY

DOSE

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

DOSE

ONCE DAILY

AT DAY 28